Therapy Detail

Therapy Name Ch282-5 + Oxaliplatin
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ch282-5 BCL2 Family Inhibitor 6 Ch282-5 is a gossypol derivative that binds to and inhibits BCL2, family proteins, resulting in decreased tumor cell growth and increased sensitivity to chemotherapeutic agents (PMID: 26515494).
Oxaliplatin Eloxatin Diaminocyclohexane Oxalatoplatinum Chemotherapy - Platinum 6 Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity (NCI Drug Dictionary). Eloxatin (oxaliplatin) is FDA approved for colorectal cancer (
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colon cancer not applicable Ch282-5 + Oxaliplatin Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of ch282-5 and Eloxatin (oxaliplatin) inhibited cell growth in human and mouse colon cancer cell lines in culture, and the combination synergized to inhibit tumor growth in mouse colon cancer cell line xenograft models (PMID: 26515494). 26515494
Clinical Trial Phase Therapies Title Recruitment Status